Z.A. GONCHAROVA, T.S. KOLMAKOVA, O.S. OKSENIUK, E.V. MORGUL, M.A. GELPEY, Yu.А. KALMYKOVA, О.B. SMIRNOVA

Rostov-on-Don State Medical University, 29 Nakhichevanskiy pereulok, Rostov-on-Don, Russian Federation, 344022

Goncharova Z.A. ― D. Sc. (medicine), Professor of the Department of Nervous Diseases and Neurosurgery, e-mail: centrms@mail.ru, ORCID ID: 0000-0001-7093-9548

Kolmakova T.S. ― D. Sc. (biology), Associate Professor, Head of the Department of Medical Biology and Genetics, e-mail: tat_kolmakova@mail.ru, ORCID ID: 0000-0002-1923-3168

Okseniuk O.S. ― PhD (medicine), Head of the Central Research Laboratory, e-mail: oksenuk_o@bk.ru, ORCID ID: 0000-0003-2592-1167

Morgul E.V. ― PhD (biology), Associate Professor of the Department of Medical Biology and Genetics, e-mail: ozoedu@mail.ru, ORCID ID: 0000-0001-6389-8872

Gelpey M.A. ― postgraduate student of the Department of Nervous Diseases and Neurosurgery, e-mail: gelpey.margo@gmail.com, ORCID ID: 0000-0002-0957-2182

Kalmykova Yu.A. ― Senior Researcher of the Central Research Laboratory, e-mail: vasil5493@rambler.ru, ORCID ID: 0000-0003-2451-4623

Smirnova O.B. ― Senior Researcher of the Central Research Laboratory, e-mail: zolochevskaj51@mail.ru

Objective ― multiparametric evaluation of immunochemical abnormalities, indices of oxidative stress and endogenous intoxication reflecting the state of the nervous system microstructures in Parkinson’s disease.

Material and methods. The study included 32 patients of the main group and 21 patients as a control group. A blood sample was taken to evaluate endogenous intoxication by detecting medium-mass molecules (MMM), assessing the state of the immune system by determining the content of circulating immune complexes (CIC), the total oxidative activity and total antioxidant activity of the organism (TOA and TAA): the activity of catalase, superoxide dismutase (SOD) and malonic dialdehyde (MDA) in blood serum by spectrophotometric method.

Results. MMM of all specters showed significant differences from the control group parameters regardless of the disease stage. When comparing the CIC level in the early and late stage groups with the control group, no significant differences were found. Indicators of SOD, catalase activity, TAA, TOA in patients with early stage of Parkinson’s disease significantly differed from those of the control group.

Conclusion. The revealed differences in all MMM spectra indicate the presence of endogenous intoxication in patients with Parkinson’s disease. A significant difference in the oxidative status of patients in the early and late stages of the disease was revealed.

Key words: Parkinson’s disease, endogenous intoxication, oxidative stress, early diagnosis.

(For citation: Goncharova Z.A., Kolmakova T.S., Okseniuk O.S., Morgul E.V., Gelpey M.A., Kalmykova Yu.A., Smirnova O.B. Multi-parametric assessment of biochemical blood markers in Parkinson’s disease. Practical Medicine. 2018)

REFERENCES

1. Goncharova Z. A., Chernikova I.V., Rabadanova E.A. et al. Modern aspects of epidemiology and early diagnosis of Parkinson’s disease. Meditsinskiy vestnik Yuga Rossii, 2014, no. 3, pp. 15-21 (in Russ.).
2. Postuma R.B., Berg D., Stern M. et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord, 2015, no. 30, pp. 1591-1601.
3. Goncharova Z.A., Rabadanova E.A., Gel’pey M.A. Non-motor symptoms of Parkinson’s disease, their structure and impact on the quality of life of patients. Prakticheskaya meditsina, 2015, no. 90 (5), pp. 111-115 (in Russ.).
4. Gasser T. Genomic and proteomic biomarkers for Parkinson disease. Neurology, 2009, vol. 72, pp. 27-31.
5. Lickera V., Kovarib E., Hochstrasserc D.F., Burkhard P.R. Proteomics in human Parkinson’s disease research. J. Proteomics, 2009, vol. 73 (1), pp. 10-29.
6. Sowell R.A., Owen J.B., Butterfield D.A. Proteomics in animal models of Alzheimer’s and Parkinson’s diseases. Ageing Res. Rev, 2009, vol. 8 (1), pp. 1-17.
7. Goncharova Z.A., Kolmakova T.S., Gel’pey M.A. Alpha-synuclein and oxidative stress enzymes as Parkinson’s biomarkers. Neyrokhimiya, 2017, no. 34 (2), pp. 99-107 (in Russ.).
8. Alvarez-Erviti L., Rodriguez-Oroz M.C., Cooper J.M. et al. Chaperone-mediated autophagy markers in Parkinson disease brains. Arch. Neurol, 2010, 67, pp. 1464-1472.
9. Schapira A.H. Mitochondrial pathology in Parkinson’s disease. Sinai J. Med, 2011, vol. 78, pp. 72-81.
10. Shadrina M.I., Slominskiy P.A. The value of mitochondrial dysfunction and oxidative damage in the molecular pathology of Parkinson’s disease. Molekulyarnaya biologiya, 2008, vol. 42 (5), pp. 809-819 (in Russ.).
11. Dorsey E.R., Constantinescu R. Projected number of people with Parkinson’s disease in the most populous nations, 2005 through 2030. Neurology, 2007, vol. 68, pp. 384-386.
12. Buneeva O.A., Medvedev A.E. Mitochondrial dysfunction in Parkinson’s disease. Biomeditsinskaya khimiya, 2011, no. 57 (3), p. 246 (in Russ.).
13. Bobela W., Aebischer P., Schneider B.L. Αlpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson’s Disease. Biomolecules, 2015, vol. 5 (4), pp. 2675-2700.
14. Karyakina E.V., Belova S.V. Medium-weight molecules as an integral indicator of metabolic disorders (literature review). Klin. lab. diag, 2004, no. 3, pp. 4-8 (in Russ.).
15. Ivanova S.A., Alifirova V.M., Semke A.V. et al. Kliniko-diagnosticheskoe znachenie molekul sredney massy u bol’nykh psikhicheskimi i nevrologicheskimi rasstroystvami: posobie dlya vrachey [Clinical and diagnostic value of medium-weight molecules in patients with mental and neurological disorders: a manual for doctors].Tomsk, 2010. 32 p.
16. Smirnova L.P., Ivanova S.A., Krotenko N.V. et al. The State of the Antioxidant System during Therapy of Patients with Multiple Sclerosis. Biochemistry (Moscow) Supplement. Series B: Biomedical Chemistry, 2011, vol. 5, no.1 (in Russ.).
17. Karyakina E.V., Belova S.V. Medium-weight molecules as an integral indicator of metabolic disorders (literature review). Klin. lab. diagn, 2004, no. 3, p. 3 (in Russ.).
18. Kryzhanovskiy G.N., Magaeva S.V. Neyroimmunopatologicheskie mekhanizmy v tipovykh patologicheskikh protsessakh v tsentral’noy nervnoy sisteme [Neuroimmunopathological mechanisms in typical pathological processes in the central nervous system]. Sb. tr. X konf. “Neyroimmunologiya”. Moscow, 28-31 May, 2001. P. 56.
19. Alves G.J., Palermo-Neto J. Neuroimmunomodulation: the cross-talk between nervous and immune systems. Rev. Bras. Psiquiatr, 2007, vol. 29 (4), rr. 363-369.
20. Bower J.H., Maraganore D.M., Peterson B.J. et al. Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study. Neurology, 2006, vol. 67 (3), rr. 494-496.
21. Katsarou Z., Bostantjopoulou S, Hatzizisi O. et al. Immune factors or depression? Fatigue correlates in Parkinson’s disease. Rev. Neurol, 2007, vol. 45 (12), rr. 725-728.
22. Monahan A.J., Warren M., Carvey P.M. Neuroinflammation and peripheral immune infiltration in Parkinson’s disease: an autoimmune hypothesis. Cell Transplant, 2008, vol. 17 (4), rr. 363-372.
23. Wang X.J., Yan Z.Q., Lu G.Q. Parkinson disease IgG and C5a-induced synergistic dopaminergic neurotoxicity: role of microglia. Neurochem. Int, 2007, vol. 50 (1), rr. 39-50.
24. Gabrielyan N.I., Lipatova V.I. Experience of using the indicator of average blood molecules for the diagnosis of nephrological diseases in children. Laboratornoe delo, 1984, no. 3, pp. 138-140 (in Russ.).
25. Goryacheva N.V., Bulava G.V., Vetoshkin A.N., Godkov M.A. Modification of the definition of circulating immune complexes of various sizes in human serum. Klinicheskaya i laboratornaya diagnostika, 1997, no. 5, pp. 77-79 (in Russ.).